Publication: 2810

Publication: 2810

Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)

DOI

URL

Google Scholar

Citation:: Annals of Oncology vol 28 (suppl_3) 153

Meeting Instance:: ESMO GI 2017
Year:: 2017
Type:: Abstract
Sub type:: Oral
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No

Parents:: None
Children:: 2802 3167

Program:: TRP
Primary Committee:: Correl Sci NOS
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, U10CA180790, U10CA180820, U10CA180835, U10CA180850, U10CA180863, U10CA180868, U10CA180888, CCSRI 021039, U24CA196067, U24CA196171

Corr. Author:
Authors:: Frank A. Sinicrope Qian Shi Fabienne Hermitte Erica N. Heying Al B. Benson Sharlene Gill Richard M. Goldberg Morton S. Kahlenberg Suresh G. Nair Anthony F. Shields Daniel J. Sargent Jérôme Galon Steven R. Alberts

Networks:

Study: NCCTG-N0147
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: immunologic adjuvants pharmaceutical adjuvants phase 3 clinical trials patient prognosis colon cancer fluorouracil/leucovorin calcium/oxaliplatin